Open AccessEfficacy of Lopinavir–Ritonavir Combination Therapy for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis
Author(s) -
Jiawen Deng,
Fangwen Zhou,
Wenteng Hou,
Kiyan Heybati,
Saif Ali,
Oswin Chang,
Zachary Silver,
Thanansayan Dhivagaran,
Harikrishnaa Ba Ramaraju,
Chi Yi Wong,
Qi Zuo,
Elizabeth Lapshina,
Madeline Mellett
Publication year - 2022
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/fvl-2021-0066
Subject(s) - lopinavir , medicine , lopinavir/ritonavir , meta analysis , ritonavir , adverse effect , incidence (geometry) , covid-19 , odds ratio , observational study , randomized controlled trial , mechanical ventilation , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , optics , infectious disease (medical specialty) , physics , disease
Aim: To evaluate the efficacy and safety of lopinavir-ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom